| Indicators | Browse All

Apollomics, Inc. (APLM)

Healthcare | Biotechnology | Foster City, United States | NasdaqCM
15.70 USD +1.49 (10.486%) ⇧ (July 14, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 5:24 a.m. EDT

The immediate outlook is severely clouded by a looming delisting threat. The company recently received a Nasdaq deficiency notice regarding minimum market value requirements, and the market has already reacted violently, with the share count dropping precipitously from over $1 billion in mid-2022 to a mere $41 million today. This collapse in capitalization creates immense volatility risk and potential liquidity issues, making any short-term trade highly speculative rather than a calculated momentum play. While the stock recently bounced off lows, the fundamental reality is stark: the business is burning cash aggressively with negative free cash flow and negative operating income, while the stock price has erased nearly 99.5% of its value over the last three years. There is no evidence of a turnaround in revenue or profitability; instead, the company faces existential regulatory hurdles that could force it off the major exchange entirely. With no dividend to provide a floor and a balance sheet showing negative book value, there is no margin of safety here. The statistical models show low confidence in the next few weeks, which aligns with the chaotic nature of a stock fighting for listing status. Investors should view this as a distressed asset with binary outcomes rather than an investment opportunity.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.150860
AutoARIMA0.150862
MSTL0.156865
AutoTheta0.173732

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 30%
H-stat 3.71
Ljung-Box p 0.000
Jarque-Bera p 0.035
Excess Kurtosis -1.06
Attribute Value
Sector Healthcare
Revenue per Share 6.115
Market Cap 34,478,016
Forward P/E -24.15
Beta 1.44
Profit Margins -123.72%
Website https://www.apollomicsinc.com

Info Dump

Attribute Value
52 Week Change 1.3683333
Address1 989 East Hillsdale Blvd.
Address2 Suite 220
All Time High 4,900.0
All Time Low 3.659
Ask 15.7
Ask Size 3
Average Daily Volume10 Day 25,610
Average Daily Volume3 Month 12,672
Average Volume 12,672
Average Volume10Days 25,610
Beta 1.436
Bid 15.27
Bid Size 4
Book Value -1.485
City Foster City
Country United States
Crypto Tradeable 0
Currency USD
Current Price 15.7
Current Ratio 0.957
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 16.9
Day Low 14.3
Display Name Apollomics
Ebitda -9,085,000
Ebitda Margins -1.02748
Enterprise To Ebitda -3.505
Enterprise To Revenue 3.602
Enterprise Value 31,845,016
Eps Forward -0.65
Eps Trailing Twelve Months -8.67
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 650 288 1674
Fifty Day Average 16.09812
Fifty Day Average Change -0.39811993
Fifty Day Average Change Percent -0.024730833
Fifty Two Week Change Percent 136.83333
Fifty Two Week High 42.12
Fifty Two Week High Change -26.419998
Fifty Two Week High Change Percent -0.62725544
Fifty Two Week Low 3.659
Fifty Two Week Low Change 12.041
Fifty Two Week Low Change Percent 3.29079
Fifty Two Week Range 3.659 - 42.12
Financial Currency USD
First Trade Date Milliseconds 1,637,937,000,000
Float Shares 1,241,867
Forward Eps -0.65
Forward P E -24.153847
Free Cashflow -9,808,500
Full Exchange Name NasdaqCM
Full Time Employees 14
Gmt Off Set Milliseconds -14,400,000
Gross Margins 1.0
Gross Profits 8,842,000
Has Pre Post Market Data 1
Held Percent Insiders 0.47104
Held Percent Institutions 0.00059
Implied Shares Outstanding 2,196,052
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,023-03-30
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,732,492,800
Last Split Factor 1:100
Long Business Summary Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Long Name Apollomics, Inc.
Market us_market
Market Cap 34,478,016
Market State PRE
Max Age 86,400
Message Board Id finmb_382083491
Most Recent Quarter 1,767,139,200
Net Income To Common -10,939,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 31,205,898
Open 15.8
Operating Cashflow -10,369,000
Operating Margins 4.31871
Payout Ratio 0.0
Phone 650 209 4055
Previous Close 14.21
Price Hint 2
Price To Book -10.572391
Price To Sales Trailing12 Months 3.8993459
Profit Margins -1.2371601
Quick Ratio 0.911
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 1.4899998
Regular Market Change Percent 10.485572
Regular Market Day High 16.9
Regular Market Day Low 14.3
Regular Market Day Range 14.3 - 16.9
Regular Market Open 15.8
Regular Market Previous Close 14.21
Regular Market Price 15.7
Regular Market Time 1,784,059,201
Regular Market Volume 166,585
Return On Assets -0.5761
Return On Equity -13.0536995
Revenue Per Share 6.115
Sand P52 Week Change 0.20365608
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 2,196,052
Shares Percent Shares Out 0.0023
Shares Short 5,144
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 1,592
Short Name Apollomics Inc.
Short Percent Of Float 0.0046
Short Ratio 0.33
Source Interval 15
State CA
Symbol APLM
Total Cash 3,276,000
Total Cash Per Share 1.492
Total Debt 643,000
Total Revenue 8,842,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -8.67
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 17.723825
Two Hundred Day Average Change -2.0238256
Two Hundred Day Average Change Percent -0.11418673
Type Disp Equity
Volume 166,585
Website https://www.apollomicsinc.com
Zip 94,404